AZN vs NVS
AstraZeneca PLC and Novartis AG, both Healthcare
Novartis AG is the larger company at $296B against $288B. On trailing earnings NVS is the cheaper of the two at a P/E of 21.2 against 26.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year NVS returned +20% against +5.4% for AZN. The RyuScore puts NVS ahead, 74 against 60 out of 100.
| Figure | AZN | NVS |
|---|---|---|
| Last close | $159 | $144 |
| Market cap | $288B | $296B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 26.2 | 21.2 |
| 1-year return | +5.4% | +20% |
| 5-year return | +57% | +103% |
| RyuScoresector-relative, 1–10 | 60/100 | 74/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AstraZeneca PLC
Revenue of $31B in H2 2025, net income $4.9B.
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.